Publication number: 20050171095
Abstract: The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1
Type:
Application
Filed:
December 31, 2004
Publication date:
August 4, 2005
Inventors:
Harry Howard, Yuhpyng Chen